Editorial & Opinion
Risk of hepatic decompensation from hepatitis B virus reactivation in hematological malignancy treatments.
| العنوان: | Risk of hepatic decompensation from hepatitis B virus reactivation in hematological malignancy treatments. |
|---|---|
| المؤلفون: | Barone M; Section of Gastroenterology, Department of Precision and Regenerative Medicine -Jonian Area- University of Bari, Bari 70124, Italy. michele.barone@uniba.it. |
| المصدر: | World journal of gastroenterology [World J Gastroenterol] 2024 Jul 07; Vol. 30 (25), pp. 3147-3151. |
| نوع المنشور: | Editorial |
| اللغة: | English |
| بيانات الدورية: | Publisher: Baishideng Publishing Group Country of Publication: United States NLM ID: 100883448 Publication Model: Print Cited Medium: Internet ISSN: 2219-2840 (Electronic) Linking ISSN: 10079327 NLM ISO Abbreviation: World J Gastroenterol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2014- : Pleasanton, CA : Baishideng Publishing Group Original Publication: Beijing : WJG Press, c1998- |
| مواضيع طبية MeSH: | Virus Activation*/drug effects , Virus Activation*/immunology , Hepatitis B virus*/drug effects , Hepatitis B virus*/immunology , Hepatitis B virus*/pathogenicity , Agammaglobulinaemia Tyrosine Kinase*/antagonists & inhibitors , Protein Kinase Inhibitors*/adverse effects , Protein Kinase Inhibitors*/therapeutic use , Hematologic Neoplasms*/immunology , Hematologic Neoplasms*/drug therapy , Hematologic Neoplasms*/virology, Humans ; Hepatitis B/virology ; Hepatitis B/diagnosis ; Hepatitis B/drug therapy ; Hepatitis B/immunology ; Risk Factors ; Antiviral Agents/therapeutic use ; Hepatitis B Antibodies/blood ; Hepatitis B Antibodies/immunology ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/immunology ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/virology ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/therapeutic use |
| مستخلص: | In this editorial, we discussed the apparent discrepancy between the findings described by Colapietro et al , in their case report and data found in the literature. Colapietro et al reported a case of hepatitis B virus (HBV)-related hepatic decompensation in a patient with chronic myeloid leukemia and a previously resolved HBV infection who was receiving Bruton's tyrosine kinase (BTK) inhibitor therapy. First of all, we recapitulated the main aspects of the immune system involved in the response to HBV infection in order to underline the role of the innate and adaptive response, focusing our attention on the protective role of anti-HBs. We then carefully analyzed literature data on the risk of HBV reactivation (HBVr) in patients with previous HBV infection who were treated with either tyrosine kinase inhibitors or BTK inhibitors for their hematologic malignancies. Based on literature data, we suggested that several factors may contribute to the different risks of HBVr: The type of hematologic malignancy; the type of therapy (BTK inhibitors, especially second-generation, seem to be at a higher risk of HBVr than those with tyrosine kinase inhibitors); previous exposure to an anti-CD20 as first-line therapy; and ethnicity and HBV genotype. Therefore, the warning regarding HBVr in the specific setting of patients with hematologic malignancies requires further investigation. Competing Interests: Conflict-of-interest statement: The author reports no relevant conflicts of interest for this article. (©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.) |
| References: | Blood. 2018 Apr 26;131(17):1987-1989. (PMID: 29490923) Leuk Lymphoma. 2023 Jan;64(1):18-29. (PMID: 36218218) Blood. 2005 Mar 15;105(6):2473-9. (PMID: 15572591) J Hepatol. 2016 Apr;64(1 Suppl):S60-S70. (PMID: 27084038) J Gastroenterol Hepatol. 2011 Jan;26 Suppl 1:123-30. (PMID: 21199523) Biomed Res Int. 2018 Dec 26;2018:2931402. (PMID: 30687740) World J Gastroenterol. 2023 Sep 7;29(33):4942-4961. (PMID: 37731995) Nat Med. 2013 Jul;19(7):859-68. (PMID: 23836236) Leuk Res. 2019 Jun;81:95-97. (PMID: 31075669) Int J Hematol. 2015 Sep;102(3):379-82. (PMID: 25842192) Blood. 2013 Jul 11;122(2):227-38. (PMID: 23719297) Int J Mol Sci. 2024 Feb 12;25(4):. (PMID: 38396884) Leuk Lymphoma. 2017 Jul;58(7):1764-1766. (PMID: 27892750) Hepatol Res. 2021 Feb;51(2):239-244. (PMID: 32978866) Arthritis Rheum. 2013 Nov;65(11):2783-90. (PMID: 23918413) World J Gastroenterol. 2024 Mar 7;30(9):1253-1256. (PMID: 38577192) Virol J. 2023 Aug 1;20(1):168. (PMID: 37528444) Hepatology. 2015 Mar;61(3):823-33. (PMID: 25418031) Gastroenterology. 2017 May;152(6):1297-1309. (PMID: 28219691) Hepatology. 2018 Apr;67(4):1560-1599. (PMID: 29405329) J Immunol. 2014 Feb 15;192(4):1597-608. (PMID: 24453250) Clin Lymphoma Myeloma Leuk. 2023 Aug;23(8):610-615. (PMID: 37150651) Hepatology. 2007 Apr;45(4):1056-75. (PMID: 17393513) Haematologica. 2022 Jun 01;107(6):1470-1473. (PMID: 35199505) Leuk Lymphoma. 2017 Apr;58(4):993-995. (PMID: 27546591) |
| فهرسة مساهمة: | Keywords: Bruton’s tyrosine kinase; Hematological malignancy; Hepatitis; Hepatitis B virus-DNA; Previously resolved hepatitis B virus infection |
| المشرفين على المادة: | EC 2.7.10.2 (Agammaglobulinaemia Tyrosine Kinase) 0 (Protein Kinase Inhibitors) EC 2.7.10.2 (BTK protein, human) 0 (Antiviral Agents) 0 (Hepatitis B Antibodies) 0 (Antineoplastic Agents) |
| تواريخ الأحداث: | Date Created: 20240715 Date Completed: 20240715 Latest Revision: 20240716 |
| رمز التحديث: | 20240716 |
| مُعرف محوري في PubMed: | PMC11238670 |
| DOI: | 10.3748/wjg.v30.i25.3147 |
| PMID: | 39006388 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2219-2840 |
|---|---|
| DOI: | 10.3748/wjg.v30.i25.3147 |